Opinion|Videos|August 20, 2024

Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

Experts discuss the results of the CORE-001 Trial.

Episodes in this series

Video content above is prompted by the following questions:

  • In the CORE-001 trial, what were the results for the primary endpoint of complete response at 24 months as well as the secondary endpoint of duration of response? What is notable about these results?
  • How do these results compare to those associated with other FDA-approved therapies and other investigational drugs?
  • What was the overall cystectomy-free survival rate, and what was this rate among patients who experienced a complete response?
  • Were there other notable efficacy outcomes?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more